Weill Cornell Genitourinary Cancer Program

09/22/2026

This , learn more about PSMA, a type of therapy transforming care on the Weill Cornell Medicine podcast. Dr. Scott Tagawa outlines what patients should know about this important type of treatment:

Podcast Episode · CancerCast · February 13 · 38m

09/14/2026

Dr. Scott Tagawa shared tips with Everyday Health for patients navigating radioligand therapy, including at-home radiation safety best practices:

Learn what to expect during radioligand therapy infusion for prostate cancer, including safety protocols, side effects, and at-home radiation precautions.

09/09/2026

If you’re impacted by , we hope you’ll join us at the 2026 ! Hear from care team experts on a wide range of topics and connect with others impacted by this disease. Learn more and RVSP: prostatesummit.org

09/01/2026

This , we invite all patients and loved ones impacted by to learn about the role of exercise in prostate cancer care, as well as how to best navigate educational and supportive resources: prostatesummit.org

08/26/2026

The 2026 brings together experts from some of NYC’s premier centers to share the latest & treatment updates, and much more. RSVP today: prostatesummit.org

08/18/2026

Join Weill Cornell Medicine, NewYork-Presbyterian Hospital, Memorial Sloan Kettering Cancer Center, and Columbia University Irving Medical Center for the 8th annual dedicated to educating and empowering patients and loved ones impacted by . All are welcome to attend, but RSVP is required: prostatesummit.org

08/17/2026

ICYMI: Earlier treatment with a targeted radioligand therapy delays metastatic progression. Check out the led by Dr. Scott Tagawa at Weill Cornell Medicine to learn more:

Adding a targeted radioligand drug earlier in treatment reduced the risk of disease progression or death by 28% for patients with a common form of metastatic prostate cancer, according to an international clinical trial led in part by Weill Cornell Medicine. The phase 3 trial tested 177Lu-PSMA-617 a...

08/14/2026

Results from the phase 3 PSMAddition led by Dr. Scott Tagawa showed that the addition of 177Lu-PSMA-617 to two other standard therapies extended survival in patients with PSMA-positive metastatic : https://bit.ly/4zjaYpl (cc: Urology Times)

The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.

08/12/2026

The Annual is happening 9/20/26 during ! Mark your 🗓️ for this free event featuring speakers on the role of exercise during & after treatment, and other new treatments: prostatesummit.org

08/07/2026

A preclinical study led by Weill Cornell Medicine found that genetically engineered CAR T-cell therapy reduces growth:

Researchers say approach could be useful for both initial treatment of bladder cancer as well as treatment refractory subsets of tumors.